Nomogram for predicting symptom severity during radiation therapy for head and neck cancer

Otolaryngology - Head and Neck Surgery (United States)

Volumn 151, Issue 4, 2014, Pages 619-626

  Sheu, Tommy ^a,b   Fuller, Clifton David ^a   Mendoza, Tito R ^a   Garden, Adam S ^a   Morrison, William H ^a   Beadle, Beth M ^a   Phan, Jack ^a   Frank, Steven J ^a   Hanna, Ehab Y ^a   Lu, Charles ^a   Cleeland, Charles S ^a   Rosenthal, David I ^a   Gunn, G Brandon ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

MD Anderson Symptom Inventory Head and Neck Module; nomogram; patient reported outcome; prediction tool; symptom burden

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CETUXIMAB; CISPLATIN; PLATINUM DERIVATIVE; TAXANE DERIVATIVE;

ADULT; ARTICLE; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CHEMORADIOTHERAPY; CLINICAL ASSESSMENT TOOL; CLINICAL EVALUATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; HEAD AND NECK CANCER; HEAD AND NECK SURGERY; HUMAN; HYPOPHARYNX CANCER; INDUCTION CHEMOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; LARYNX CANCER; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MD ANDERSON SYMPTOM INVENTORY HEAD AND NECK MODULE; MIDDLE AGED; MOUTH CANCER; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; NASOPHARYNX CANCER; NOMOGRAM; NOSE CANCER; OROPHARYNX CANCER; OUTCOME ASSESSMENT; PARANASAL SINUS CANCER; PATIENT REPORTED OUTCOME; PHYSICIAN; PREDICTOR VARIABLE; PRIMARY TUMOR; PROSPECTIVE STUDY; SALIVARY GLAND CANCER; SCORING SYSTEM; SYMPTOM; TERTIARY HEALTH CARE; THYROID CANCER; TRACHEA CANCER; TREATMENT DURATION; ADVERSE EFFECTS; COMPLICATION; HEAD AND NECK NEOPLASMS; PREDICTIVE VALUE; PSYCHOLOGY; RADIATION INJURY; RISK ASSESSMENT; SELF REPORT; SEVERITY OF ILLNESS INDEX;

FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NOMOGRAMS; PATIENT OUTCOME ASSESSMENT; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RADIATION INJURIES; RADIOTHERAPY; RISK ASSESSMENT; SELF REPORT; SEVERITY OF ILLNESS INDEX;

EID: 84908887641     PISSN: 01945998     EISSN: 10976817     Source Type: Journal    
DOI: 10.1177/0194599814545746     Document Type: Article

References (28)

1. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst. 1999 ; 91: 2081-2086
2. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003 ; 349: 2091-2098
3. Murphy BA, Beaumont JL, Isitt J, et al. Mucositis-related morbidity and resource utilization in head and neck cancer patients receiving radiation therapy with or without chemotherapy. J Pain Symptom Manage. 2009 ; 38: 522-532
4. Xiao C, Hanlon A, Zhang Q, et al. Symptom clusters in patients with head and neck cancer receiving concurrent chemoradiotherapy. Oral Oncol. 2013 ; 49: 360-366
5. Lughezzani G, Briganti A, Karakiewicz PI, et al. Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature. Eur Urol. 2010 ; 58: 687-700
6. Valdagni R, Kattan MW, Rancati T, et al. Is it time to tailor the prediction of radio-induced toxicity in prostate cancer patients? Building the first set of nomograms for late rectal syndrome. Int J Radiat Oncol Biol Phys. 2012 ; 82: 1957-1966
7. Turk DC, Dworkin RH, McDermott MP, et al. Analyzing multiple endpoints in clinical trials of pain treatments: IMMPACT recommendations. Initiative on methods, measurement, and pain assessment in clinical trials. Pain. 2008 ; 139: 485-493
8. Cleeland CS, Sloan JA, Cella D, et al. Recommendations for including multiple symptoms as endpoints in cancer clinical trials: a report from the ASCPRO (assessing the symptoms of cancer using patient-reported outcomes) multisymptom task force. Cancer. 2013 ; 119: 411-420
9. Nutting CM, Morden JP, Harrington KJ, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2011 ; 12: 127-136
10. Le QT, Kim HE, Schneider CJ, et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study. J Clin Oncol. 2011 ; 29: 2808-2814
11. Cleeland CS, Sloan JA. Assessing the symptoms of cancer using patient-reported outcomes (ASCPRO): searching for standards. J Pain Symptom Manage. 2010 ; 39: 1077-1085
12. Turk DC, Dworkin RH, Allen RR, et al. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain. 2003 ; 106: 337-345
13. Reeve BB, Burke LB, Chiang YP, et al. Enhancing measurement in health outcomes research supported by agencies within the US Department of Health and Human Services. Qual Life Res. 2007 ; 16: 175-186
14. Gotay CC, Kawamoto CT, Bottomley A, et al. The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol. 2008 ; 26: 1355-1363
15. Gunn GB, Mendoza TR, Fuller CD, et al. High symptom burden prior to radiation therapy for head and neck cancer: a patient-reported outcomes study. Head Neck. 2012: 1490-1498
16. Rosenthal DI, Mendoza TR, Chambers MS, et al. Measuring head and neck cancer symptom burden: the development and validation of the M. D. Anderson Symptom Inventory, Head and Neck Module. Head Neck. 2007 ; 29: 923-931
17. Salama JK, Stenson KM, List MA, et al. Characteristics associated with swallowing changes after concurrent chemotherapy and radiotherapy in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2008 ; 134: 1060-1065
18. Bond SM, Dietrich MS, Murphy BA. Association of age and symptom burden in patients with head and neck cancer. ORL Head Neck Nurs. 2011 ; 29: 8-14
19. Chen SC, Liao CT, Chang JT. Orofacial pain and predictors in oral squamous cell carcinoma patients receiving treatment. Oral Oncol. 2011 ; 47: 131-135
20. Best SR, Ha PK, Blanco RG, et al. Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma. Head Neck. 2011 ; 33: 1727-1734
21. Machtay M, Moughan J, Farach A, et al. Hypopharyngeal dose is associated with severe late toxicity in locally advanced head-and-neck cancer: an RTOG analysis. Int J Radiat Oncol Biol Phys. 2012 ; 84: 983-989
22. Terrell JE, Ronis DL, Fowler KE, et al. Clinical predictors of quality of life in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2004 ; 130: 401-408
23. Borggreven PA, Verdonck-de Leeuw IM, Muller MJ, et al. Quality of life and functional status in patients with cancer of the oral cavity and oropharynx: pretreatment values of a prospective study. Eur Arch Otorhinolaryngol. 2007 ; 264: 651-657
24. Harrell FE Regression Modeling Strategies. New York, NY: Springer-Verlag ; 2001 :
25. Motulksky H, Christopoulos A New York, NY: Oxford University Press; ; 2004 :
26. Bese NS, Hendry J, Jeremic B. Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation. Int J Radiat Oncol Biol Phys. 2007 ; 68: 654-661
27. Hunter KU, Schipper M, Feng FY, et al. Toxicities affecting quality of life after chemo-IMRT of oropharyngeal cancer: prospective study of patient-reported, observer-rated, and objective outcomes. Int J Radiat Oncol Biol Phys. 2013 ; 85: 935-940
28. Oskam IM, Verdonck-de Leeuw IM, Aaronson NK, et al. Prospective evaluation of health-related quality of life in long-term oral and oropharyngeal cancer survivors and the perceived need for supportive care. Oral Oncol. 2013 ; 49: 443-448